Kartos Therapeutics Inc
Kartos Therapeutics Inc, based in Redwood City, CA, is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapeutics aimed at significantly improving the lives of cancer patients. Their lead investigational drug, navtemadlin (KRT232), is a potent and selective oral MDM2 inhibitor designed to provide new treatment options for patients with selected solid tumors and hematological malignancies.
The company focuses on advancing its research through active clinical studies and is committed to the science of cancer treatment, emphasizing the importance of targeted therapies. With a mission centered on breakthrough therapies, Kartos Therapeutics is at the forefront of innovation in the fight against cancer.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.